Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 13 Neoplasm Metastasis 3 Colorectal Neoplasms 3 Triple Negative Breast Neoplasms 2 Endometrial Neoplasms 2 Solid Tumors 1 PIK3CA-Mutated Cancers 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm, Residual 1 Metastatic Castration-Resistant Prostate Cancer 1 Hereditary Sensory and Autonomic Neuropathies 1 HER2-positive Breast Cancer 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Trastuzumab 30 pertuzumab 16 Docetaxel 16 pyrotinib 11 Paclitaxel 7 Carboplatin 5 Capecitabine 5 Ado-Trastuzumab Emtansine 4 tucatinib 3 trastuzumab deruxtecan 2 atezolizumab 2 Protons 2 Fulvestrant 2 pegfilgrastim 1 palbociclib 1 neratinib 1 liposomal doxorubicin 1 inavolisib 1 exemestane 1 envafolimab 1 dalpiciclib 1 Taxoids 1 Neoadjuvant Therapy 1 Metformin 1 Leuprolide 1 Letrozole 1 Isovaleryl-CoA Dehydrogenase 1 Injections 1 Goserelin 1 Fluorodeoxyglucose F18 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × HER2-positive Breast Cancer × inavolisib × Clear all

NCT05306041 2025-02-17

GeparPiPPa

GBG Forschungs GmbH

Phase 2 Recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡